Status:
COMPLETED
Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis
Lead Sponsor:
Wayne Fujita, M.D.
Conditions:
Pityrosporum Folliculitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Pityrosporum folliculitis presents as fine superficial follicular pustules and papules on the trunk and upper extremities. Ketoconazole 2% foam was recently approved for the treatment of seborrheic de...
Detailed Description
Malassezia/pityrosporum species is a ubiquitous saprophyte of human skin. This organism is implicated in the etiology of seborrheic dermatitis, tinea versicolor, and pityrosporum folliculitis. The pre...
Eligibility Criteria
Inclusion
- Diagnosis of pityrosporum folliculitis will be established by clinical presentation - fine, superficial follicular papules and pustules on the chest, back, and upper arms. KOH will be done on the pustules looking for spores and hyphae.
- Concomitant acne treatments with standard acne treatment modalities will be allowed - oral and topical antibiotics, topical retinoids, and benzoyl peroxides.
Exclusion
- Pregnancy and breast feeding
- Patients with nodulocystic acne on the trunk
- Current or prior treatment with oral isotretinoin
- Patients allergic to the ketoconazole topical foam product
- Patients with associated serious systemic diseases or immunocompromised patients
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00824863
Start Date
December 1 2008
End Date
June 1 2010
Last Update
August 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aiea Medical Building; Suite 401
‘Aiea, Hawaii, United States, 96701